Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Klaria Pharma Holding AB's Debt-to-Equity or its related term are showing as below:
FRA:6FN'
s Debt-to-Equity Range Over the Past 10 Years
Min: -2.08 Med: 0.23 Max: 6.98
Current: -1.21
During the past 12 years, the highest Debt-to-Equity Ratio of Klaria Pharma Holding AB was 6.98. The lowest was -2.08. And the median was 0.23.
FRA:6FN's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.27
vs FRA:6FN: -1.21
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Klaria Pharma Holding AB Debt-to-Equity Related Terms
Klaria Pharma Holding AB Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Klaria Pharma Holding AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Klaria Pharma Holding AB Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Klaria Pharma Holding AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Klaria Pharma Holding AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Klaria Pharma Holding AB (FRA:6FN) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Klaria Pharma Holding AB and its competitors. According to the industry distribution chart, Klaria Pharma Holding AB ranks #999999 out of 814 companies in the Drug Manufacturers industry.
Is Klaria Pharma Holding AB's Debt-to-Equity too high?
Klaria Pharma Holding AB's current Debt-to-Equity is 0.00. Based on the distribution chart, Klaria Pharma Holding AB ranks #999999 out of 814 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Klaria Pharma Holding AB has a GF Score™ of 9/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Klaria Pharma Holding AB's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Klaria Pharma Holding AB ranks #999999 out of 814 companies for Debt-to-Equity. This places Klaria Pharma Holding AB in the lower half of its industry. The industry median Debt-to-Equity is 0.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Klaria Pharma Holding AB and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Klaria Pharma Holding AB's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klaria Pharma Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Klaria Pharma Holding AB (FRA:6FN) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.03, compared to a current price of €0.07 — trading 131% above its estimated fair value. The current Debt-to-Equity is 0.00. Klaria Pharma Holding AB's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Klaria Pharma Holding AB (FRA:6FN), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Klaria Pharma Holding AB (FRA:6FN) Overvalued in 2026?
Based on GuruFocus' analysis, Klaria Pharma Holding AB stock appears to be overvalued.
The current stock price of €0.07 is trading 131% above its estimated GF Value™ of €0.03.
GuruFocus considers Klaria Pharma Holding AB to be Significantly Overvalued.
Key valuation signals for FRA:6FN:
Debt-to-Equity: 0.00
GF Value™: €0.03 vs. price of €0.07 (131% above fair value)
No single metric tells the full story. See the FRA:6FN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Its patented drug delivery platform consists of an alginate-based polymer film that enables the absorption of a product's active substance through the oral mucosa.
9GF Score
Get the complete analysis for FRA:6FN
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6FN has been successfully added to your 
